Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy

Biochemical Pharmacology

Volumn 59, Issue 7, 2000, Pages 733-739

  Sessler, Jonathan L ^a   Miller, Richard A ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

Photoangioplasty; Photodynamic therapy; Radiation sensitization; Texaphyrins

Indexed keywords

GADOLINIUM CHELATE; GADOLINIUM TEXAPHYRIN; LANTHANIDE COMPLEX; LUTETIUM COMPLEX; LUTETIUM TEXAPHYRIN; METAL COMPLEX; PHOTOFRIN; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; RADIOSENSITIZING AGENT; TEXAPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOPLASTY; ATHEROSCLEROSIS; BRAIN METASTASIS; BREAST CANCER; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOSENSITIZATION; RECURRENT CANCER; RETINA MACULA DEGENERATION; REVIEW; TUMOR CELL LINE;

EID: 0033983719     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00314-7     Document Type: Article

References (42)

1. Mody T.D., Sessler J.L. Porphyrin- and expanded porphyrin-based diagnostic and therapeutic agents. Reinhoudt D. Supramolecular Technology. 1999;245-299 Wiley, Chichester.
2. Sessler J.L., Hemmi G., Mody T.D., Murai T., Burrell A., Young S.W. Texaphyrins Synthesis and applications . Acc Chem Res. 27:1994;43-50.
3. Young S.W., Qing F., Harriman A., Sessler J.L., Dow W.C., Mody T.D., Hemmi G.W., Hao Y., Miller R.A. Gadolinium(III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI . Proc Natl Acad Sci USA. 93:1996;6610-6615.
4. Young S.W., Woodburn K.W., Wright M., Mody T.D., Fan Q., Sessler J.L., Dow W.C., Miller R.A. Lutetium texaphyrin (PCI-0123) A near-infrared water-soluble photosensitizer . Photochem Photobiol. 63:1996;892-897.
5. Sessler J.L., Tvermoes N.A., Guldi D.M., Mody T.D., Allen W.E. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A. 103:1999;787-794.
6. Davis D.G. Electrochemistry of porphyrins. Dolphin D. The Porphyrins. 1978;127-152 Academic Press, New York.
7. Beard C.J., Coleman C.N., Kinsella T.J. Radiation sensitizers. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer Principles & Practice of Oncology . 1993;2701-2713 J. B. Lippincott, Philadelphia.
8. Hall E.J. Radiosensitizers and bioreductive drugs. Hall E.J. Radiobiology for the Radiobiologist. 1994;165-181 J. B. Lippincott, Philadelphia.
9. Brada M., Ross G. Radiotherapy for primary and secondary brain tumors. Curr Opin Oncol. 7:1995;214-219.
10. Coleman C.N. Radiation and chemotherapy sensitizers and protectors. Chabner B.A., Long D.L. Cancer Chemotherapy and Biotherapy. 1996;553-583 Lippincott-Raven, Philadelphia.
11. Wasserman T.H., Chapman J.D., Coleman C.N., Kligerman M.M. Chemical modifiers of radiation. Peres C.A., Brady L.W. Principles and Practice of Radiation Oncology. 1998;685-704 Lippincott-Raven, Philadelphia.
12. Wasserman T.H., Stetz J.A., Phillips T.L. Radiation therapy group clinical trials with misonidazole. Cancer. 47:1981;2382-2390.
13. Kinsella T.J., Russo A., Mitchell J.B., Rowland J., Jenkins J., Schwade J., Myers C.E., Collins J.M., Speyer J., Kornbluth P., Smith B., Kufta C., Glatstein E. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys. 10:1984;69-76.
14. Miller R.A., Woodburn K., Fan Q., Renschler M., Sessler J.L., Koutcher J.A. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 45:1999;981-999.
15. Timmerman B., Carde P., Koprowski C., Arwood D., Ford J., Mehta M., Tishler R., Larner J., Miller R., Koffler-Horovitz S., Hoth D., Renschler M. Phase Ib/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases Final results . Int J Radiat Oncol Biol Phys. 42:(Suppl):1998;198.
16. Rosenthal D.I., Nurenberg P., Becerra C.R., Frenkel E.P., Carbonne D.P., Lum B.L., Miller R., Engel J., Young S., Miles D., Renschler M.F. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 5:1999;739-745.
17. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S.A., Petit P.X., Mignotte B., Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 182:1995;367-377.
18. Papa S., Skulchev V.P. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem. 174:1997;305-319.
19. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat Med. 3:1997;1034-1036.
20. Dougherty T.J., Henderson B.W., Schwartz S., Winkelman J.W., Lipson R.L. Historical perspective. Henderson B.W., Dougherty T.J. Photodynamic Therapy, Basic Principles and Clinical Applications. 1992;1-18 Marcel Dekker, New York.
21. Pass H.I. Photodynamic therapy in oncology Mechanisms and clinical use . J Natl Cancer Inst. 85:1993;443-456.
22. Morgan A.R. Strategies for the development of photodynamic sensitizers. Curr Med Chem. 2:1995;604-615.
23. Kessel D. Photodynamic therapy of neoplastic disease. Drugs Today. 32:1996;385-396.
24. Rouhi AM, Let there be light and let it heal. C & E News, November 2, 1998: 22-27, 1998.
25. Woodburn K.W., Young S.W., Miller R.A. Influence of drug and light regimens in determining PDT efficacy with lutetium texaphyrin. Proc SPIE Int Opt Eng. 2675:1996;172-178.
26. Woodburn K.W., Fan Q., Miles D.R., Kessel D., Luo Y., Young S.W. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem Photobiol. 65:1997;410-415.
27. Woodburn K.W., Fan Q., Kessel D., Luo Y., Young S.W. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. Invest Dermatol. 110:1998;746-751.
28. Renschler M.F., Yuen A.R., Panella T.J., Wieman T.J., Dougherty S., Esserman L., Panjehpour M., Taber S.W., Fingar V.H., Lowe E., Engel J.S., Lum B., Woodburn K.W., Cheong W.-F., Miller R.A. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer. Proc SPIE Int Opt Eng. 3247:1998;35-39.
29. Woodburn K.W., Young S.W., Qing F., Miles D.R., Thiemann P. Light emitting diode versus laser irradiation phototherapy with lutetium texaphyrin (PCI-0123). Proc SPIE Int Opt Eng. 2972:1997;46-53.
30. Woodburn K.W., Fan Q., Kessel D., Wright M., Mody T.D., Hemmi G., Madga D., Sessler J.L., Dow W.C., Miller R.A., Young S.W. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg. 14:1996;343-348.
31. Sessler J.L., Dow W.C., O'Connor D., Harriman A., Hemmi G., Mody T.D., Miller R.A., Qing F., Springs S., Woodburn K., Young S.W. Biomedical applications of lanthanide(III) texaphyrins. Lutetium(III) texaphyrins as potential PDT photosensitizers. J Alloys Compd. 249:1997;146-152.
32. Woodburn K.W., Qing F., Kessel D., Young S.W. Photoeradication and imaging of atheromatous plaque with texaphyrins. Proc SPIE Int Opt Eng. 2970:1997;44-50.
33. Woodburn K.W., Young S.W., Fan Q., Kessel D., Miller R. Selective uptake of texaphyrins by atheromatous plaque. Proc SPIE Int Opt Eng. 2671:1996;62-71.
34. Arbour J.D., Connolly E.J., Graham K., Carson D., Michaud N., Flotte T., Gragoudas E.S., Miller J.W. Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin. Invest Ophthalmol Vis Sci. 40:1999;S401.
35. Graham K.B., Arbour J.D., Connolly E.J., Delori F., Carson D., Gragoudas E.S., Miller J.W. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 40:1999;S402.
36. Wan S., Parrish J.A., Anderson R.R., Madden M. Transmittance of nonionizing radiation in human tissues. Photochem Photobiol. 34:1981;679-681.
37. Grossweiner LI, Fernandez JM, Bilgin MB and Mody TD, Singlet oxygen generation by metallotexaphyrins. Photochem Photobiol, in press.
38. Bellnier D.A., Dougherty T.J. A preliminary pharmacokinetic study of intravenous photofrin in patients. J Clin Laser Med Surg. 14:1996;311-314.
39. Kramer P., Rockson S., Razavi M., Adelman D. ANTRIN™ photoangioplasty Results of a Phase I trial of a novel therapeutic modality in patients with lower extremity arterial atherosclerosis . Eur Heart J. 20:1999;1555.
40. Boyle R.W., Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol. 64:1996;469-485.
41. Magda D, Miller RA, Wright M, Rao J, Sessler JL, Iverson BL and Sansom PI, Texaphyrin-based nuclease analogs, Rationally designed approaches to the catalytic cleavage of RNA and DNA targets. In: DNA and RNA Cleavers and Chemotherapy of Cancer and Viral Disease (Ed. Meunier B), NATO ASI Series C, Vol. 479, pp. 337-353. Kluwer, Amsterdam, 1996.
42. Magda D.M., Wright M., Crofts S., Lin A., Sessler J. Metal complex conjugates of antisense DNA which display ribozyme-like activity. J Am Chem Soc. 119:1997;6947-6948.